Experience in neuromuscular diseases in children and adolescents and their comorbidities in a tertiary hospital

J. A. Gascón-Navarro 1†, M. J. De La Torre-Aguilar 1*, J. A. Fernández-Ramos 2,3, J. Torres-Borrego 4† and J. L. Pérez-Navero 1,3

Abstract

Introduction: Neuromuscular diseases include a large group of heterogeneous and rare pathologies that affect different components of the motor unit. It is essential to optimize resources to know the prevalence of comorbidities in the most frequent groups to establish an early multidisciplinary approach in a specialized setting.

Patients and methods: Retrospective descriptive study of pediatric and adolescent patients with neuromuscular diseases (NMDs). The inclusion criteria were NMDs patients with motor neuron involvement divided into three groups, depending on the affected component of the motor unit. Group I: involvement of the motor neuron; Group II: peripheral neuropathies; Group III: myopathies. Demographic variables, association with comorbidities, need for respiratory support, and rehabilitative treatment were collected in each group.

Results: Ninety-six patients who met the inclusion criteria were studied. In group I, when compared to the other two groups, a higher incidence of scoliosis (68.3%, p = 0.011), deformity of the rib cage (31.3%, p = 0.0001), chronic respiratory insufficiency (62.5%, p = 0.001) and bronchial aspiration (12.5%, p = 0.03) was detected. In this group, 50% of the patients required non-invasive mechanical ventilation (p = 0.0001). The in-hospital requirement for respiratory physiotherapy was higher in group I (75%, p = 0.001). We observed a higher incidence of scoliosis in Group III compared to Group II.

Conclusions: Neuromuscular diseases with motor neuron involvement present more comorbidities and require an early approach after diagnosis to improve prognosis.

Introduction

Neuromuscular diseases (NMDs) comprise a wide range of syndromes, constituting more than 150 pathologies, including motor neuron involvement, peripheral neuropathy, myopathies, and neuromuscular junction disorders [1]. Muscle weakness is a feature shared by all these conditions. A good knowledge of the natural history of each NMDs is essential to guarantee the optimal time for therapeutic interventions and the start of rehabilitation. In some of these syndromes, the presenting manifestation is a functional sign or deformity. The timing of the treatment of spinal deformities is crucial, due to the hypotonia of the paraspinous musculature during growth. A multidisciplinary approach is always required, muscular and respiratory physiotherapy being key.

In NMDs, the musculoskeletal system is affected early, which compromises the acquisition of motor milestones, especially the development of gait and stability [2]. Loss of muscle strength has a negative impact on the skeletal...
Respiratory rehabilitation has been a radical change in anticipatory diagnostic and genetic therapies where appropriate. Currently, there has been a significant evolution lately. New considerations of care are intended to better address the patients’ needs; provide current advances in assessment and interventions, as well as considering emerging molecular and genetic therapies where appropriate. Current advances in assessment and interventions, as well as considering emerging molecular and genetic therapies where appropriate. Currently, there has been a radical change in anticipatory diagnostic and therapeutic strategies. Respiratory rehabilitation is key for addressing NMDs. Two fundamental groups of rehabilitative techniques have been described, some facilitate the functioning of the diaphragm, the elimination of secretions, lung compliance, glossohypopharyngeal respiration and increase lung volumes, and other techniques are employed for the mobilization and prevention of musculoskeletal spasticity and stiffness.

We considered it of interest to carry out a descriptive study of patients with neuromuscular disorders, and this has revealed there exist an incidence of comorbidities and a need to prioritize rehabilitation in the groups of diseases that are expected to be greater in morbidity and mortality.

Patients and methods
Descriptive retrospective study of pediatric and adolescent patients with neuromuscular diseases admitted to a Neuropediatric Unit at a tertiary hospital. The selected patients were divided into the three groups, these being most frequent in our setting, depending on the affected component of the motor unit: Group I: involvement of the motor neuron; Group II: peripheral neuropathies; Group III: myopathies.

Exclusion criteria
Patients with involvement of neuromuscular junction. Likewise, the groups of the classification of genetically based neuromuscular diseases 2020 version.

Inclusion criteria
NMDs patients with motor neuron involvement, with peripheral neuropathies and myopathies.

The variables that were collected in the three study groups were: demographics, associated neurological, musculoskeletal, respiratory, cardiac and digestive comorbidities, as well as the need for in-hospital respiratory and musculoskeletal physiotherapy. The criteria for prioritizing the indication for respiratory physiotherapy were: where the onset of respiratory insufficiency, as well as the presence of deformity of the chest and/or scoliosis. Depending on the clinical situation of each patient, the rehabilitation physicians of the multidisciplinary team, using the same criteria, indicated different rehabilitation methods: 1) Techniques to facilitate the functioning of the diaphragm and the elimination of secretions, manual or mechanical cough assistance, slow expiration with the glottis opened in lateral decubitus position, slow expiration technique, autogenous drainage, increased expiratory flow, directed cough, forced expiration techniques, active cycle of breathing techniques, controlled inspiratory debit exercises, flow spirometer. 2) Techniques to mobilize and prevent musculoskeletal spasticity and stiffness: kinesitherapy and the Vojta, and Le Metayer Methods.

Data were obtained from the medical history of each participant after the patient’s parents or legal guardians had signed the informed consent. This study was approved by the Hospital’s Biomedical Ethics Committee and conformed to ethical standards established in the Declaration of Helsinki of 1964. Data are expressed as mean ± SD (95% confidence intervals), median (IQR) or absolute (relative frequencies). For data that fitted a normal distribution (Shapiro-Wilk normality test) t-tests were used. Comparisons among groups were made by Kruskal-Wallis test or ANOVA. Categorical variables were assessed using the χ² test or the Fisher exact test. All the tests were two-tailed, and the results were considered statistically significant when the p value was < 0.05. Data were analyzed with the SPSS 23.0 program (SPSS Inc., Chicago, Illinois, United States).

Results
One hundred and three patients with NMDs admitted to the Neuropediatric Unit at our hospital were studied. Seven patients were excluded because they did not meet the inclusion criteria. From the analysis of the database, 96 patients met the inclusion criteria. The underlying pathologies presented according to the group in which
patients were included: Group I: Motor neuron involvement; Spinal Muscular Atrophy (15 patients): SMA-1: 4, of them, 1 was being treated with Risdiplam, and 3 cases of SMA-1b received Nusinersen. All of them were in the sitting or standing phase. SMA-2: 11 patients. Of them, 7 received Nusinersen and 4 Risdiplam, with stabilization of their disease, measured by motor scales [23–25] and number of respiratory infections. Group II: peripheral neuropathies (40 patients): 34 chronic hereditary sensory motor neuropathies, 2 Peripheral Facial Paralysis, 1 Cranial Polyneuropathy, 1 Parsonage-Turner Syndrome, 2 Guillain-Barré Syndrome. Group III: Myopathies (41 patients): 34 Muscular Dystrophies, 4 Congenital Myopathies, 2 Hipokaliemia Periodic Paralysis, 1 Mitochondrial Myopathies.

Age (years) Group I: 15 ± 9.93 years; group II: 13.33 ± 4.5 years; group III: 11.82 ± 4.9 years (p: 0.06). Sex (male): Group I: 12 (80%); group II: 17 (42.5%); group III: 23 (56.1%) p: 0.03. When comparing the incidence of comorbidities in the three study groups, significance was observed in group I with involvement of the motor neuron in: Scoliosis (p < 0.05), Rib cage deformities (p < 0.001), Lung infection (p < 0.001), bronchial aspiration (p < 0.023), chronic respiratory insufficiency (0.001). When comparing the incidence of comorbidities in the three study groups, significance was observed in group I in: Scoliosis (p < 0.05), Rib cage deformities (p < 0.001), Lung infection (p < 0.001), bronchial aspiration (p < 0.023), chronic respiratory insufficiency (0.001). No significance was obtained in myocardiopathy, deglutition disorders, gastroesophageal reflux disease, sleep apnea-hypopnea syndrome and nocturnal hypoventilation.

The prevalence of the digestive pathologies was higher in Group I (33.3%) when compared to Group II (10%) and III (12.2%) (Table 1).

Table 1 displays the early initiation of respiratory and musculoskeletal physiotherapy, depending on the affected component of the motor unit, as well as the need for non-invasive ventilation (NIV), tracheostomy, and invasive mechanical ventilation (IMV). Group I showed significant differences with respect to the other two study groups regarding the need for early indication for respiratory physiotherapy (p < 0.002) and non-invasive ventilation (p < 0.001).

**Discussion**

In the present study of a series of children and adolescents with NMDs, it has been observed that Group I with motor neuron involvement presents a higher incidence of comorbidities. It is suggested, in the context of a multi-disciplinary approach, to initiate early rehabilitation treatment in this group of patients, which could improve its prognosis. Most NMDs are rare inherited conditions that have a relentlessly progressive course. Many worsen due to musculoskeletal, respiratory, digestive, nutritional, or heart problems. Some NMDs are associated with intellectual disability. For this reason, NMDs care is more beneficial when it is provided by a multidisciplinary team of professionals working together.

The rehabilitation of patients with NMDs should include physical, daily activities performance, as well as the need for assistive devices assessments. With adequate physical, psychological and social support, patients can thus maintain a good quality of life [15, 17].

It is important to start proactive respiratory care, as the great variety of different neuromuscular diseases require careful planning of the treatment strategies in each case by the multidisciplinary team [2, 8, 22]. In our series, respiratory physiotherapy included different manual or mechanical techniques, such as cough assistance, slow expiration, increased expiratory flow, directed cough, forced expiration, active cycle of breathing, and flow spirometer. At the same time, kinesitherapy and the Vojta or the Le Metayer methods were applied to mobilize and prevent musculoskeletal spasticity and stiffness. Since our retrospective series of pediatric and adolescent patients with neuromuscular diseases was classified into three different pathology groups, depending on the affected component of the motor unit, to perform the same type of respiratory and musculoskeletal...

| **Table 1** Comorbidities associated with neuromuscular diseases |
|---------------------------------------------------------------|
| **Group I (n = 15)** | **Group II (n = 40)** | **Group III (n = 41)** | **P** |
|----------------------|----------------------|----------------------|------|
| Scoliosis            | 10 (66.7%)<sup>ab</sup> | 11 (27.5%) | 14 (34.1%)<sup>ab</sup> | 0.025 |
| Rib cage deformities | 4 (26.7%)<sup>ab</sup> | 0 | 0 | < 0.001 |
| Myocardiopathy       | 2 (13.3%)<sup>ab</sup> | 0 | 2 (4.9%)<sup>ab</sup> | 0.064 |
| Deglutition disorders y/o GERD | 5 (33.3%)<sup>ab</sup> | 4 (10%)<sup>ab</sup> | 5 (12.2%)<sup>ab</sup> | 0.119 |
| Lung infection       | 8 (53.3%)<sup>ab</sup> | 8 (20%)<sup>ab</sup> | 3 (7.3%)<sup>ab</sup> | 0.001 |
| Bronchial aspiration | 2 (13.3%)<sup>ab</sup> | 4 (10%)<sup>ab</sup> | 0 | 0.023 |
| SAHS /Nocturnal hypoventilation | 3 (20%)<sup>ab</sup> | 1 (2.5%)<sup>ab</sup> | 2 (4.9%)<sup>ab</sup> | 0.114 |
| Chronic respiratory insufficiency | 9 (60%)<sup>ab</sup> | 4 (10%)<sup>ab</sup> | 4 (9.8%)<sup>ab</sup> | 0.001 |

<sup>ab</sup> Group I Involvement of the motor neuron; Group II: Peripheral neuropathies; Group III: Myopathies. SAHS Sleep apnea-hypopnea syndrome, GERD - Gastroesophageal reflux disease - <sup>a</sup> p < 0.05 between group I and group II; <sup>b</sup> p < 0.05 between group I and group III
physiotherapy in all patients was not possible, as its indication depends on the patients’ clinical situation and age. The main objective of this work was to study the incidence of comorbidities in each group to benefit from the therapeutic resources in physiotherapy and rehabilitation, and to approach to the most serious patients with these, which should be standardized.

NMDs patients with respiratory dysfunction require rehabilitation before performing surgery [11]. In cases without respiratory dysfunction, early physiotherapy is not required; however, surgical correction can trigger exacerbation and respiratory insufficiency. Respiratory dysfunction can manifest with dyspnea, worsening fatigue, an increased frequency of lower respiratory tract infections, and diaphoresis. Signs of nocturnal hypoventilation are manifested by agitation during sleep, headache, or nausea upon awakening, as well as drowsiness during the day and decreased concentration. By means of pulmonary function tests and polysomnography, an objective evaluation of daytime and/or nocturnal chronic alveolar hypoventilation can be made. Depending on the results of these tests, different physiotherapy techniques are indicated considering age and pathology. Where necessary, non-invasive ventilation (NIV) is indicated at night and/or during the day. On the other hand, inpatients at high risk of respiratory insufficiency, the possible need for tracheostomy should be considered and, depending on the patient’s clinical situation, IMV should be indicated to improve lung expansion [19].

When addressing NMDs, we considered, as suggested by Estrup et al. [26], the training of the respiratory muscles, which could improve vital capacity and resistance to muscle fatigue. In neuromuscular diseases, respiratory physiotherapy is of vital importance, as it facilitates the maintenance of lung function and reduces the incidence of lung infections [2]. In our study, despite respiratory physiotherapy was performed more intensively in Group I with motor neuron involvement than in Group II and III, this group presented a greater number of complications, that is, more cases required NIV, tracheostomy and IMV. This was to be expected, since the incidence of respiratory disease in Group I was higher. Preventive indication for early respiratory physiotherapy in these patients could improve lung expansion and volume and prevent a decline in the respiratory function.

It is important to consider that children with NMDs also have secondary osteoporosis. Low bone mass in these patients causes greater bone fragility and risk of fracture [27, 28]. In our study, Group I showed the highest prevalence of musculoskeletal pathology and digestive disorders, as other authors have as well reported [29–31]. Weakness of the intercostal muscles, scoliosis, respiratory insufficiency, and infections are the main complications that Group I patients presented.

Regarding musculoskeletal physiotherapy, as well in Group I, it is more common to find contractures in the limbs, musculoskeletal spasticity, and rigidity [16, 18]. There is controversy among authors in relation to the approach to neuromuscular diseases, sleep disorders, as well as reducing the incidence of respiratory pathology. Chatwin et al. [6] have suggested the use of NIV; however, Marques et al. [31] and Toussaint et al. [32] have advised the use of a self inflating bag to perform hyperinflation and thus increase the maximum peak of assisted and unassisted cough. In our series, we utilized NIV routinely as respiratory support. Concerning Group II with peripheral neuropathies, the prevalence of comorbidities was lower than in Group I. On the other hand, the incidence of lung infection and bronchial aspiration was higher in Group II than in Group III, although without significance. As described by Pons et al. [33], Group II patients frequently present phrenic nerve paralysis, which per se causes respiratory insufficiency. In order to address patients in this group, Darquennes et al. [34] have recommended the use of nocturnal NIV to treat respiratory disease, as with Group I. We followed a similar pattern. Group III also presented a lower prevalence of comorbidities than Group I. We observed a higher incidence of scoliosis in Group III than in Group II. Consequently, neuromuscular diseases with motor disturbance present more comorbidities in children and adolescents, which is due to central affection. On the contrary, in Groups II and III with neuropathies and myopathies, the injury is more peripheral and localized.

| Table 2 Respiratory treatment and rehabilitation | Group I (n = 16) | Group II (n = 41) | Group III (n = 42) | P |
|-------------------------------------------------|----------------|-----------------|-----------------|---|
| **Musculoskeletal Physiotherapy**               | 13 (86.7%)     | 30 (75%)        | 25 (61%)        | 0.117 |
| **Respiratory physiotherapy**                   | 11 (73.3%)     | 9 (22.5%)       | 13 (31.7%)      | 0.002 |
| **NIV**                                         | 7 (46.7%)      | 3 (7.5%)        | 2 (4.9%)        | < 0.001 |
| **Tracheotomy**                                 | 1 (6.7%)       | 1 (2.5%)        | 1 (2.4%)        | 0.742 |
| **IMV**                                         | 1 (6.7%)       | 1 (2.5%)        | 1 (2.4%)        | 0.759 |

*Group I Involvement of the motor neuron; Group II: Peripheral neuropathies; Group III: Myopathies*

*NIV Non-invasive ventilation, IMV Invasive mechanical ventilation. a: p < 0.05 between group I and group II; b: p < 0.05 between group I and group III*
The present study is of interest since, based on our results, we suggest a large multicenter prospective study to know the incidence of comorbidities in NMDs and to prioritize an approach to these. The major strength of this study is that it was conducted in a single center with minimal variability in data collection, establishing restrictive and objective inclusion criteria.

When studying neuromuscular diseases in children and adolescents in our environment, we observed that, in Group I with motor neuron disturbance, there was also a greater musculoskeletal involvement, rib cage deformity and scoliosis, as well as a higher prevalence of lung infection, bronchial aspiration, and a greater need for NIV. Respiratory and musculoskeletal physiotherapeutic treatment was indicated more intensively in Group I patients. The patients with motor neuron involvement, as they presented more comorbidities, required a narrower multidisciplinary approach, in which early rehabilitative treatment, from the onset of diagnosis, was key to improve their prognosis.

Acknowledgements
No applicable.

Authors’ contributions
GNJ analyzed the data and drafted the manuscript; FRIA, TBJ carried out the clinical evaluation; PNJL, TAMJ designed the study, collected and analyzed the data. All the authors have read and approved the final version of the manuscript.

Funding
Not applicable.

Availability of data and materials
The datasets used are available from DLTA on reasonable request.

Declarations

Ethics approval and consent to participate
This protocol was approved by the Clinical Research and Bioethics Committee at Reina Sofia University Hospital, Córdoba (Spain), conforming to the fundamental ethical principles laid down in the Declaration of Helsinki. Informed written consent was obtained from the parents or legal guardians of each participant before testing.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Pediatrics. Reina Sofia University Hospital, Córdoba University, Maimónides Biomedical Research Institute of Córdoba (BMIRIC), Avd. Menéndez Pidal s/n, PC, 14004 Córdoba, Spain. 2Neopaticology Unit. Department of Pediatrics. Reina Sofia University Hospital, Córdoba University, Córdoba, Spain. 3Center for Biomedical Research on Rare Diseases (CIBERER), ISCIII, Madrid, Spain. 4Pediatric Pulmonology Unit, Department of Pediatrics. Reina Sofia University Hospital, Córdoba University, Córdoba, Spain.

Received: 17 January 2021 Accepted: 23 October 2021
Published online: 16 November 2021

References
1. Martínez Carraco C, Villa Asensi JR, Luna Paredes MC, Osoña Rodríguez De Torres FB, Peña Zarza JA, Larramona Carrera H, et al. Enfermedad neuromuscular: evaluación clínica y seguimiento desde el punto de vista neurológico. AnPediatr. 2014;81:258–61. 258a17. https://doi.org/10.1016/j.an pediatr.2014.02.024.
2. Mary P, Servais L, Vaille R. Neuromuscular diseases: diagnosis and management. OrthopTraumaSurg Res. 2018;104(1):589–95. https://doi.org/10.1016/j.otsr.2017.04.019.
3. Gayraud J, Ramonatxo M, Rivet F, Humberclaude V, Petrof B, Matecki S. Ventilatory parameters and maximal respiratory pressure changes with age in duchenne muscular dystrophy patients. Pediatri Pulmonol. 2010;45(6): 552–9. https://doi.org/10.1002/ppul.21204.
4. Tangsruad SE, Petersen IL, LØdrupCarlsen KC, Carlsen KH. Lung function in children with Duchenne’s muscular dystrophy. Respir Med. 2001;95(11):898–903. https://doi.org/10.1053/rmed.2001.1177.
5. Avendaño M, Güell R. Rehabilitación en pacientes con enfermedades neuromusculares y concomitancias de la caja torácica. Arch Bronconeumol. 2003;39(12):559–65. https://doi.org/10.1016/S0000-2896(03)75455-6.
6. Chatwin M, Bush A, Simonds AK. Outcome of goal-directed non-invasive ventilation and mechanical insufflation/exsufflation in spinal muscular atrophy type I. Arch Dis Child. 2011;96(5):426–32. https://doi.org/10.1136/adc.2009.177832.
7. Feingold B, Mähle WT, Auerbach S, Clemenst P, Domenighetti AA, Jefferies JL, et al. Management of Cardiac Involvement Associated with Neuromuscular Diseases: a scientific statement from the American Heart Association. Circulation. 2017;136(13):e200–31. https://doi.org/10.1161/CIR. 0000000000000526.
8. Perrin C, Unterborn JD, Ambrosio CD, Hill NS. Pulmonary complications of chronic neuromuscular diseases and their management. Muscle Nerve. 2004;29(1):5–27. https://doi.org/10.1002/mus.10487.
9. Bimkramt DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018;17(3):251–67. https://doi. org/10.1016/S1474-4422(18)30024-3.
10. Hull J, Aniapravann R, Chan E, Chatwin M, Fenton J, Gallagher J, et al. British Thoracic Society guideline for respiratory management of children with neuromuscular weakness. Thorax. 2012;67(Suppl. 1):1–40. https://doi.org/1 0.1136/thoraxjnl-2012-201916.
11. Finder JD. A 2009 perspective on the 2004 American thoracic society statement, “respiratory care of the patient with Duchenne muscular dystrophy”. Pediatrics. 2009;123(Suppl 4):S239–41. https://doi.org/10.1542/ peds.2008-29521.
12. Chatwin M, Simonds AK. Long-term mechanical insufflation–Exsufflation cough assistance inNeuromuscular disease: patterns of use and lessons for application. Respir Care. 2020;65(2):135–43. https://doi.org/10.4187/respcare. 06882.
13. Lanza FC, Santos Alves C, dos Santos RL, Alves de Camargo A, Dal Conso S. Respiratory ReserveVolume During Slow Expiration With Glottis Opened inInfralateral Decubitus Position (ELTGOL) inChronic Pulmonary Disease: Technique Description and Reproducibility. Respir Care. 2015;60:406–11. https://doi.org/10.4187/respcare.03384.
14. Rodillo E, Noble-Jamieson CM, Aber V, Heckmatt JZ, Muntoni F, Dubowitz V. Respiratory muscletraining in Duchenne muscular dystrophy. Arch Dis Child. 1989;64(5):736–41. https://doi.org/10.1136/adc.64.5.736.
15. Vanasse M, Paré H, Zeller R. Medical and psychosocial considerations in rehabilitation care ofchildren neuromuscular diseases. HandbClin Neurol. 2013;113:1491–5. https://doi.org/10.1016/B978-0-444-59565-2.00019-8.
16. Dricoll SW, Skinner J. Musculoskeletal complications of neuromuscular disease inChildren. Phys Med RehabilClin N Am. 2008;19(1):163–94, viii. https://doi.org/10.1016/j.pmr.2007.10.003.
17. Watzek I, Winterholler M. Basic principles of non- respiratory physiotherapy for neuromuscular diseases. Pulmonology. 2008;62(Suppl 1):528–30. https:// doi.org/10.1055/s-2007-1016426.
18. Vivancos-Matellano F, Pascual-Pascual SI, Nardi-Viardaga J, Miquel-Rodriguez F, de Miguel-Leon I, Martinez-Garre MC, et al. Spanish group on spasticity.
Guide to the comprehensive treatment of spasticity. Rev Neurol. 2007;45(6):365–75.

19. Khirani S, Bersanini C, Aubertin G, Bachy M, Vialle R, Fauroux B. Non-invasive positive pressure ventilation to facilitate the post-operative respiratory outcome of spine surgery in neuromuscular children. Eur Spine J. 2014;23(Suppl 4):S406–11. https://doi.org/10.1007/s00586-014-3335-6.

20. Benaroch L, Bonne G, Rivier F, Hambrou D. The 2020 version of the genetic table of neuromuscular disorders (nuclear genome). Neuromuscul Disord. 2019;29(12):980–1018. https://doi.org/10.1016/j.nmd.2019.10.010.

21. Silva IS, Pedroso R, Azevedo IG, Forbes AM, Fregonezi GA, Dourado Junior ME, et al. Respiratory muscle training in children and adults with neuromuscular disease. Cochrane Database Syst Rev. 2019;5(9):CD011711. https://doi.org/10.1002/14651858.CD011711.pub2.

22. Buu MC. Respiratory complications, management and treatments for neuromuscular disease in children. Curr Opin Pediatr. 2017;29(3):326–33. https://doi.org/10.1097/MOP.0000000000000498.

23. Main M, Kairon H, Mercuri E, Muntoni F. The Hammersmith functional motor scale for children with spinal muscular atrophy: a scale to test ability and monitor progress in children with limited ambulation. Eur J Paediatr Neurol. 2003;7(4):155–9. https://doi.org/10.1016/s1090-3798(03)00060-6.

24. Capella-Peris C, Emile-Backer M, Shelton MO, Chrismier IC, Cosgrove MM, Bendixen RM, et al. Development of a proxy-reported scale to assess motor function in infants and young children with early-onset neuromuscular disorders. J Adv Nurs. 2021;77:1591–608. https://doi.org/10.1111/jan.14687.

25. Holtebekk ME, Berntsen S, Rasmussen M, Jahnsen RB. Physical activity and motor function in children and adolescents with neuromuscular disorders. Pediatr Phys Ther. 2013;25(4):415–20. https://doi.org/10.1097/PEP.0b013e3182a63580.

26. Estrup C, Lyager S, Noeraa N, Olsen C. Effect of respiratory muscle training in patients with neuromuscular diseases and in normals. Respiration. 1986;50(1):36–43. https://doi.org/10.1159/000194904.

27. Iolascon G, Paoletta M, Liguori S, Curci C, Moretti A. Neuromuscular Diseases and Bone. Front Endocrinol (Lausanne). 2019;10:794. https://doi.org/10.3389/fendo.2019.00794.

28. Yaşar E, Adıgüzel E, Arslan M, Matthews DJ. Basics of bone metabolism and osteoporosis in common pediatric neuromuscular disabilities. Eur J Paediatr Neurol. 2018;22(11):17–26. https://doi.org/10.1016/j.ejpn.2017.08.001.

29. Martinez Carasco C,Cols Roig M, Salcedo Posadas A, Sardon Prado O, Asensio De La Cruz O, Torrent Vernetta A. Respiratory treatments in neuromuscular disease. An Pediatr. 2014;81:259.e1–9. https://doi.org/10.1016/j.anpedi.2014.04.008.

30. Kolb SJ, Kissel JT. Spinal muscular atrophy. Neurol Clin. 2015;33(4):831–46. https://doi.org/10.1016/j.ncl.2015.07.004.

31. Marques TBC, de Neves JC, Portes LA, Salge JM, Zanoteli E, Reed UC. Air stacking: effects on pulmonary function in patients with spinal muscular atrophy and in patients with congenital muscular dystrophy. J Bras Pneumol. 2014;40(5):528–34. https://doi.org/10.1590/s1806-37132014000500009.

32. Toussaint M, Pernet K, Steens M, Haan J, Sheers N. Cough augmentation in subjects with Duchenne muscular dystrophy: Comparison of air stacking via a resuscitator bag versus mechanical ventilation. Respir Care. 2016;61:61–7. https://doi.org/10.4187/respcare.04033.

33. Pons Ódena M, Piqué-Mariambaldo I, Colomer Oferli J, Segura Matute S, Palomeque Rico A. Enfermedad respiratoria y parálisis diafragmática en la enfermedad de Charcot-Marie-Tooth. An Pediatr. 2010;72:267–71. https://doi.org/10.1016/j.anpedi.2009.11.017.

34. Darquennes K, De Jonghe P, Daens D, De Backer W, Verbraken J. Intermittent positive airway pressure by nasal mask as a treatment for respiratory insufficiency in a patient with Charcot-Marie-Tooth disease. Acta Clin Belg. 2006;61(4):176–81. https://doi.org/10.1179/arc.2006.030.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.